Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

March 2021; 8 (2) Clinical/Scientific NotesOpen Access

Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody–Positive Patient

David Gritsch, Amir A. Mbonde, Ehab Y. Harahsheh, View ORCID ProfileBrian W. Chong, Dean M. Wingerchuk
First published January 19, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000956
David Gritsch
From the Department of Neurology (D.G., A.A.M., E.Y.H., D.M.W.), and Department of Neuroradiology (B.W.C.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir A. Mbonde
From the Department of Neurology (D.G., A.A.M., E.Y.H., D.M.W.), and Department of Neuroradiology (B.W.C.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: abdallah.amir@mayo.edu
Ehab Y. Harahsheh
From the Department of Neurology (D.G., A.A.M., E.Y.H., D.M.W.), and Department of Neuroradiology (B.W.C.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: harahsheh.ehab@mayo.edu
Brian W. Chong
From the Department of Neurology (D.G., A.A.M., E.Y.H., D.M.W.), and Department of Neuroradiology (B.W.C.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian W. Chong
  • For correspondence: chong.brian@mayo.edu
Dean M. Wingerchuk
From the Department of Neurology (D.G., A.A.M., E.Y.H., D.M.W.), and Department of Neuroradiology (B.W.C.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wingerchuk.dean@mayo.edu
Full PDF
Citation
Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody–Positive Patient
David Gritsch, Amir A. Mbonde, Ehab Y. Harahsheh, Brian W. Chong, Dean M. Wingerchuk
Neurol Neuroimmunol Neuroinflamm Mar 2021, 8 (2) e956; DOI: 10.1212/NXI.0000000000000956

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
801

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Organ-specific and nonorgan-specific autoimmune diseases commonly coexist with aquaporin-4 antibody (AQP4-IgG)–positive neuromyelitis optica spectrum disorder (NMOSD). We report an unusual case in which a young woman with known systemic lupus erythematosus (SLE) was discovered to be AQP4-IgG seropositive when she developed simultaneous severe longitudinally extensive transverse myelitis, reversible intracranial vasculopathy, cutaneous vasculitis, and myocarditis. We discuss the pathogenic mechanisms that may underlie systemic and CNS disease activity in these coexisting diseases.

Case Description

A 27-year-old woman with a 10-year history of SLE treated with mycophenolate mofetil and hydroxychloroquine was transferred to our facility for rapidly progressive sensorimotor paraparesis with areflexia, a thoracic sensory level (T6–T8), and urinary retention that developed over 36 hours. Her symptoms started 6 days earlier with fever, headache, nausea, vomiting, back spasms, and pruritic skin eruptions involving the right cheek, left shoulder, upper back, and lower abdomen.

Spinal MRI showed extensive T2 hyperintensity involving the entire spinal cord from the conus to the lower medulla (figure, A.a–e). CSF analysis showed lymphocytic pleocytosis (152 nucleated cells per microliter with 85% lymphocytes, 8.5% neutrophils, 5.2% monocytes, and 1.3% eosinophils), hypoglycorrhachia of 29 mg/dL, elevated CSF protein of 299 mg/dL, negative oligoclonal bands, and elevated CSF IgG index of 1.94. Laboratory testing showed elevated inflammatory markers (C-reactive protein 25.2 mg/dL and erythrocyte sedimentation rate 19 mm/h), low complement levels (C3 47 mg/dL, C4 13 mg/dL), and positive titers for antinuclear antibodies, anti-Ro (SS-A), and DNA double-stranded antibodies (>12 U, >8 U and 305 IU/mL, respectively), as well as elevated cardiac markers (troponin T 157 ng/L, creatinine kinase 1,387 U/L, and N-terminal-pro hormone BNP8198 pg/mL). Serum AQP4-IgG was positive at a titer of >1:100,000; myelin oligodendrocyte glycoprotein and antiphospholipid antibodies were negative. Transthoracic echocardiogram demonstrated reduced left ventricular ejection fraction of 49%, and skin biopsy of the rash demonstrated leukocytoclastic vasculitis (figure, E.a and b). Brain MRI demonstrated scattered, nonenhancing T2 hyperintensities in the deep subcortical white matter, brainstem, and cerebellum and a punctate periventricular infarct (figure, B.a and b). MRI brain angiogram (MRA) on day 3 of admission showed segmental narrowing and dilation involving small and medium sized vessels (figure, C.a and b).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Simultaneous Transverse Myelitis, Reversible Cerebral Vasculopathy, and Cutaneous Vasculitis

(A.a) Sagittal T2-weighted fast spin echo (FSE) MRI of the thoracic spine demonstrating extensive T2 hyperintensity of the entire thoracic cord and involving the cervical cord (image not shown). (A.b) Sagittal T1-weighted MRI spine without gadolinium contrast. (A.c) Sagittal T1-weighted MRI spine with gadolinium contrast demonstrating mild and diffuse thoracic cord enhancement. (A.d) Axial T2-weighted FSE, (A.e) axial T1-weighted precontrast and (A.f) postcontrast thoracic spine images all taken at the same level (white line) demonstrating centrally located T2 hyperintense and enhancing lesions (arrowhead). (B.a) Fluid-attenuated inversion recovery MRI of the brain demonstrating scattered, nonenhancing T2 hyperintensities in the deep subcortical white matter (arrows). (B.b) Diffusion-weighted imaging reveals a punctate right periventricular focus of diffusion restriction (arrow), with corresponding correlate on apparent diffusion coefficient imaging (not shown). (C.a and C.b) MRI brain angiogram (MRA) on day 3 of admission showing segmental narrowing (arrows) and dilation (arrowheads) involving the right M1 middle cerebral artery (C.a), right A1 anterior cerebral artery (C.a), and right P1 posterior cerebral artery (C.b). (D.a and D.b) repeat MRA on day 12 of admission showing significant improvement in the appearance of the intracranial vasculature. (E.a) Patient's photograph depicting an erosive skin rash in the left paraumbilical region. (E.b) Skin biopsy of the rash demonstrating leukocytoclastic vasculitis with perivascular neutrophilic (arrows) and histiocytic dermal inflammation with marked fibrin deposition (asterixes) surrounding thin-walled superficial vessels (hematoxylin-eosin; original magnification ×400).

A diagnosis of NMOSD with AQP4-IgG and SLE-related CNS vasculopathy and/or vasculitis was made. Treatment with IV methylprednisolone, plasma exchange, and one cycle of IV cyclophosphamide was initiated. On day 12 of admission, the patient developed severe thunderclap headache and repeated MRA showed significant improvement in the appearance of the intracranial vasculature (figure, D.a and b), suggesting reversible vasoconstriction rather than vasculitis as the likely mechanism. The patient was transitioned to oral mycophenolate mofetil and IV rituximab. At the 6-month follow-up, the patient showed significantly improved quadriparesis with good grip strength and antigravity movement in lower extremities.

Discussion

NMOSD is a rare but well-documented and potentially devastating coincident disease in patients with SLE.1 A high prevalence of AQP4-IgG had previously been demonstrated in patients with connective tissue disease and clinical signs of NMOSD.2 More recently, Asgari et al.3 examined the prevalence of AQP4-IgG in a prospective cohort of 208 patients with SLE and reported AQP4-IgG in only 2 of 30 patients with neuropsychiatric SLE (NPSLE), both of whom had myelitis. These findings demonstrate that AQP4-IgG retain a high specificity for NMOSD in the setting of SLE, suggesting 2 distinct but overlapping disease entities.

The simultaneous occurrence of active SLE, AQP4-NMOSD, and CNS vasculopathy in our case is intriguing and raises important questions as to whether common disease mechanisms exist. Interestingly, Birnbaum et al. had described a subset of patients with SLE-myelitis and similar presentation of flaccidity-hyporeflexia, inflammatory prodrome, and urinary retention in the setting of active SLE. However, unlike in our case, most of these were AQP4-IgG seronegative.4 Serum-derived autoantibodies are central in the pathogenesis of AQP4-NMOSD and thought to mediate several pathologic manifestations in NPSLE.5 Furthermore, complement activation is a critical mediator of tissue damage in both SLE and AQP4-NMOSD.6 Notably, production of proinflammatory cytokines, immune complex formation, and vascular injury in NPSLE can lead to disruption of the blood-brain barrier (BBB) and facilitate CNS entry of pathogenic autoantibodies.7

To our knowledge, this is the first reported case of AQP4-IgG positive NMOSD with reversible cerebral vasculopathy in the setting of active SLE. Systemic inflammation, complement activation, and increased permeability of the BBB are important mechanisms in NPSLE and may be contributing factors to both vascular injury and NMOSD. A better understanding of the pathogenic mechanisms involved will be instrumental in developing future preventative and therapeutic strategies.

Study Funding

The authors report no targeted funding.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • The Article Processing Charge was funded by the authors.

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • Received October 11, 2020.
  • Accepted in final form December 3, 2020.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Wingerchuk DM,
    2. Weinshenker BG
    . The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler J 2012;18:5–10.
    OpenUrl
  2. 2.↵
    1. Jarius S,
    2. Jacobi C,
    3. De Seze J, et al
    . Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler J 2011;17:1067–1073.
    OpenUrl
  3. 3.↵
    1. Asgari N,
    2. Jarius S,
    3. Laustrup H, et al
    . Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler J 2018;24:331–339.
    OpenUrl
  4. 4.↵
    1. Birnbaum J,
    2. Petri M,
    3. Thompson R,
    4. Izbudak I,
    5. Kerr D
    . Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009;60:3378–3387. doi: 10.1002/art.24937.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Schwartz N,
    2. Stock AD,
    3. Putterman C
    . Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019;15:137–152.
    OpenUrlPubMed
  6. 6.↵
    1. Thurman JM,
    2. Yapa R
    . Complement therapeutics in autoimmune disease. Front Immunol 2019;10:672. doi: 10.3389/fimmu.2019.00672.
    OpenUrl
  7. 7.↵
    1. Hammer C,
    2. Stepniak B,
    3. Schneider A, et al
    . Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2014;19:1143–1149.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case Description
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Autoimmune diseases
  • Lupus
  • Devic's syndrome
  • Vasculitis
  • Transverse myelitis

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise